Employers Pepsi, Starbucks and Cigna Are Dropping GLP-1 Coverage. At 65, Medicare May Cover Zepbound for Sleep Apnea or Wegovy for Heart Risk, With Part D Spending Capped at $2,400 in 2027
PepsiCo, Cigna, and Starbucks have dropped GLP-1 weight loss drug coverage for employees, citing rising costs. Medicare may cover certain GLP-1s for specific conditions, with Part D out-of-pocket cap rising to $2,400 in 2027. CMS offers a $50/month Bridge program for some GLP-1s until December 2027.
How this was made
The 30-second read
Why it matters
The policy shift affects employee benefit costs but has limited direct impact on the companies' core financials; indirect pressure may fall on GLP‑1 drug manufacturers.
Market read
The article informs investors of a new employer cost‑management measure; limited immediate trading relevance for the listed firms.
What to watch
Potential increase in out‑of‑pocket spending by employees could boost pharmacy‑benefit manager revenues.
Background
Employers PepsiCo, Cigna, and Starbucks are removing coverage for expensive GLP‑1 weight‑loss medications, while Medicare introduces a $50 bridge program for eligible patients.
Ticker impact
PepsiCo announced it is dropping coverage for GLP‑1 weight‑loss drugs for employees, keeping only diabetes coverage.
neutral as the change mainly affects employee benefits costs, not core business.
The announcement concerns internal benefit policy; no direct revenue impact and market has not priced a move.
Cigna stopped covering GLP‑1s for weight loss in its employee health plan on July 1.
neutral; the policy shift affects only internal costs, not the insurer's underwriting results.
No immediate financial impact disclosed; investors typically view employee‑benefit tweaks as low‑impact.
Starbucks ended coverage for eligible employees for GLP‑1 weight‑loss drugs in October.
neutral; the change is limited to employee benefits and does not alter core operations.
The announcement is a cost‑management measure with negligible effect on revenue or margins.
Market effects
May signal broader employer pushback on costly GLP‑1 drugs, potentially affecting pharma demand outlook.
U.S. employer benefit policies; limited regional effect.
Low; primarily U.S. corporate benefit decisions.
Counterpoint
If employer coverage cuts reduce demand for GLP‑1 drugs, pharma companies could see pressure, creating short opportunities.
Key entities
- companyPepsiCo
Food and beverage conglomerate
- companyCigna
Health insurance provider
- companyStarbucks
Coffeehouse chain
